Capecitabine and Oxaliplatin in the Preoperative Multimodality Treatment of Rectal Cancer: Surgical End Points From National Surgical Adjuvant Breast and Bowel Project Trial R-04 von O'CONNELL, Michael J, COLANGELO, Linda H, PARDA, David S, MOHIUDDIN, Mohammed, ARORA, Amit, EVANS, Lisa S, BAHARY, Nathan, SOORI, Gamini S, EAKLE, Janice, ROBERTSON, John M, MOORE, Dennis F, MULLANE, Michael R, BEART, Robert W, MARCHELLO, Benjamin T, WARD, Patrick J, WOZNIAK, Timothy F, ROH, Mark S, YOTHERS, Greg, WOLMARK, Norman, PETRELLI, Nicholas J, ALLEGRA, Carmen J, SHARIF, Saima, PITOT, Henry C, SHIELDS, Anthony F, LANDRY, Jerome C, RYAN, David P

Volltext

Avelumab or talazoparib in combination with binimetinib in metastatic pancreatic ductal adenocarcinoma: dose-finding results from phase Ib of the JAVELIN PARP MEKi trial von Rodon Ahnert, J., Tan, D.S.-W., Garrido-Laguna, I., Harb, W., Bessudo, A., Beck, J.T., Rottey, S., Bahary, N., Kotecki, N., Zhu, Z., Deng, S., Kowalski, K., Wei, C., Pathan, N., Laliberte, R.J., Messersmith, W.A.

Volltext

A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative tumor hENT1 expression von Li, D, Pant, S, Ryan, D.P, Laheru, D, Bahary, N, Dragovich, T, Hosein, P.J, Rolfe, L, Saif, M.W, LaValle, J, Yu, K.H, Lowery, M.A, Allen, A, O'Reilly, E.M

Volltext

Phase I/II Trial of Autophagy Inhibition in Combination with Neoadjuvant Gemcitabine in High Risk Pancreatic Adenocarcinoma: Safety and Response to Treatment von Boone, B.A, Zureikat, A, Bahary, N, Bartlett, D.L, Amaravadi, R, Lotze, M.T, Zeh, H.J

Volltext

Interim Analysis of a Phase II Clinical Trial of Induction Gemcitabine/Capecitabine followed by SABR in Borderline/Locally Advanced Pancreatic Adenocarcinoma von Quan, K, Rajagopalan, M.S, Clump, D.A, Wegner, R.E, Burton, S, Flickinger, J.C, Stoller, R, Lembersky, B, Bahary, N, Zeh, H, Heron, D.E

Volltext

Stereotactic Body Radiation Therapy in Treatment of Adenocarcinoma of Pancreas in Elderly Patients von Ling, D, Kim, C.H, Wegner, R.E, Heron, D.E, Zeh, H.J, Moser, A.J, Bahary, N, Ozhasoglu, C, Quinn, A.E, Burton, S.A

Volltext

Tales from the deep: reeling in renal failure von Bahary, Nathan

Volltext

Development. Endothelium--chicken soup for the endoderm von Bahary, N, Zon, L I

Volltext

Stereotactic Body Radiation Therapy for Liver Oligometastases in Pancreatic Cancer: Enhancing Precision and Outcomes von Sourial, F., Shamsesfandabadi, P., Wegner, R.E., Kirichenko, A.V., Monga, D., Bahary, N., Beriwal, S., Renz, P.B.

Volltext

1475P Results of a randomized, double-blind, placebo-controlled, phase II study of gemcitabine and nab-paclitaxel ± olaratumab in treatment-naïve patients with unresectable metastatic pancreatic cancer von Gardner, F., Wainberg, Z., Fountzilas, C., Bahary, N., Womack, M., Mercada, T.M., Garrido-Laguna, I., Peterson, P.M., Ceccarelli, M., Pelzer, U.

Volltext

1555P Real-world treatment patterns and effectiveness of liposomal irinotecan in a NAPOLI1-based regimen among patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): A multi-academic center chart review von Yu, K.H., Hendifar, A., Alese, O., Draper, A., Abdelrahim, M., Burns, E., Khan, G., Cockrum, P., Bhak, R., Nguyen, C., DerSarkissian, M., Duh, M.S., Bahary, N.

Volltext

Stereotactic Body Radiotherapy (SBRT) in the Treatment of Locally-advanced, Recurrent, and Unresectable and Pancreatic Adenocarcinoma von Rwigema, J, Parikh, S.D, Burton, S.A, Quinn, A.E, Bahary, N, Lembersky, B.C, Zeh, H.J, Stoller, R.G, Howell, M, Heron, D.E

Volltext

Neoadjuvant Chemotherapy Resulting in Suboptimal CA19-9 Response is Associated with No Survival Benefit Compared to Surgery First Approach in Resectable or Borderline Resectable Pancreatic Cancer von Liu, H., D'Alesio, M., Al Masri, S., Hammad, A., Desilva, A., Ashwat, E., Hampton, E., Lebowitz, S., Singhi, A., Bahary, N., Lee, K., Zureikat, A., Paniccia, A.

Volltext

Is Adjuvant Chemotherapy Needed in Surgically Resected Pancreatic Carcinoma with Node Negative Disease Following Neoadjuvant Therapy? A Multi-Institutional Analysis von Hammad, A., Almasri, S., Hodges, J., Paniccia, A., Lee, K., Bahary, N., Singhi, A., Ellsworth, S., Evans, D., Tsai, S., Zureikat, A.

Volltext

Stereotactic Radiosurgery in Patients with Resected Pancreatic Carcinomas with Positive Margins von Parikh, S.D, Burton, S.A, Heron, D.E, Zeh, H.J, Moser, A.J, Bahary, N, Lembersky, B.C, Ozhasoglu, C, Quinn, A

Volltext

The systemic immune-inflammation index (SII) predicts neoadjuvant therapy response and survival in patients with pancreatic cancer who are CA 19-9 non-secretors von Murthy, P., Zenati, M., AlMasri, S., DeSilva, A., Bahary, N., Singhi, A., Ellsworth, S., Paniccia, A., Lee, K., Lotze, M., Zureikat, A.

Volltext

CA19-9 reduction correlates to histopathologic tumor response following neoadjuvant chemotherapy in pancreatic adenocarcinoma von Kim, V.M., AlMasri, S., Zenati, M., Hoehn, R.S., Hammad, A.Y., Singhi, A.D., Bahary, N., Ellsworth, S.G., Lee, K.K., Paniccia, A., Zureikat, A.H.

Volltext

Presence of perineural invasion determines the need for adjuvant chemotherapy in resected pancreatic carcinoma with node negative disease following neoadjuvant therapy; a multi-institutional analysis von Hammad, A.Y., AlMasri, S., Hodges, J.C., Paniccia, A., Lee, K.K., Bahary, N., Singhi, A., Aldakkak, M., Evans, D.B., Tsai, S., Zureikat, A.

Volltext

Randomized phase 2 study of PEGPH20 Plus nab-paclitaxel/gemcitabine (PAG) vs AG in patients (Pts) with untreated, metastatic pancreatic ductal adenocarcinoma (mPDA) von Hingorani, S.R., Bullock, A., Seery, T., Zheng, L., Sigal, D., Ritch, P.S., Braiteh, F.S., Zalupski, M., Bahary, N., Harris, W., Pu, J., Aldrich, C., Khelifa, S., Wu, W., Chondros, D., Jiang, P., Hendifar, A.

Volltext

Tumor hyaluronan (HA) is a novel biomarker: Results of the randomized phase 2 HALO 202 study of PEGPH20 plus nab-paclitaxel/gemcitabine (PAG) vs AG in previously untreated, metastatic pancreatic ductal adenocarcinoma (mPDA) von Hendifar, A., Bullock, A., Seery, T., Zheng, L., Sigal, D., Ritch, P.S., Braiteh, F.S., Zalupski, M., Bahary, N., Harris, W., Pu, J., Lian, F., Zhu, J., Wu, W., Chondros, D., Jiang, P., Hingorani, S.R.

Volltext